The need for multiple tumour results for carriers of a given variant is implemented to minimize the chance of acquired somatic changes, such as MLH1 promoter methylation and now biallelic somatic mutations [24,25], being the cause of tumour MMR deficiency rather than the presence of a pathogenic mutation. This evidence concerns the gene MLH1 and neoplasm.